Terms: = Prostate cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2
270 results:
1. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
2. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Ahlberg M; Garmo H; Stattin P; Gedeborg R; Edlund C; Holmberg L; Bill-Axelson A
Scand J Urol; 2024 Mar; 59():63-69. PubMed ID: 38482602
[TBL] [Abstract] [Full Text] [Related]
3. Carboxylesterase-overexpressing htert-immortalized human adipose stem cells in prostate tumor growth inhibition by irinotecan.
Kim JH; Oh E; Song ES; Yun CW; Lee SH; Song YS
J Cancer Res Ther; 2023 Oct; 19(7):1731-1742. PubMed ID: 38376272
[TBL] [Abstract] [Full Text] [Related]
4. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.
Franco FB; Leeman JE; Fedorov A; Vangel M; Fennessy FM
Clin Radiol; 2024 Apr; 79(4):e607-e615. PubMed ID: 38302377
[TBL] [Abstract] [Full Text] [Related]
5. Testosterone replacement therapy: clinical considerations.
Luther PM; Spillers NJ; Talbot NC; Sinnathamby ES; Ellison D; Kelkar RA; Ahmadzadeh S; Shekoohi S; Kaye AD
Expert Opin Pharmacother; 2024; 25(1):25-35. PubMed ID: 38229462
[TBL] [Abstract] [Full Text] [Related]
6. Testosterone replacement in men with sexual dysfunction.
Lee H; Hwang EC; Oh CK; Lee S; Yu HS; Lim JS; Kim HW; Walsh T; Kim MH; Jung JH; Dahm P
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013071. PubMed ID: 38224135
[TBL] [Abstract] [Full Text] [Related]
7. prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract] [Full Text] [Related]
8. SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide cancer Therapy.
Lee K; Lall R; Chopra S; Evans MJ; Maharbiz MM; Seo Y; Anwar M
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1575-1584. PubMed ID: 38122990
[TBL] [Abstract] [Full Text] [Related]
9. Synthesis and Preclinical Evaluation of PSMA-Targeted
Santos JF; Braz MT; Raposinho P; Cleeren F; Cassells I; Leekens S; Cawthorne C; Mendes F; Fernandes C; Paulo A
Mol Pharm; 2024 Jan; 21(1):216-233. PubMed ID: 37992229
[TBL] [Abstract] [Full Text] [Related]
10. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis and biological evaluation of novel salicylidene uracils: Cytotoxic activity on human cancer cell lines and inhibitory action on enzymatic activity.
Poslu AH; Aslan ŞE; Koz G; Senturk E; Koz Ö; Senturk M; Nalbantsoy A; Öztekin A; Ekinci D
Arch Pharm (Weinheim); 2024 Jan; 357(1):e2300374. PubMed ID: 37902389
[TBL] [Abstract] [Full Text] [Related]
12. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract] [Full Text] [Related]
13. Accelerator-Based Production of Scandium Radioisotopes for Applications in prostate cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Meier JP; Zhang HJ; Freifelder R; Bhuiyan M; Selman P; Mendez M; Kankanamalage PHA; Brossard T; Pusateri A; Tsai HM; Leoni L; Penano S; Ghosh K; Broder BA; Markiewicz E; Renne A; Stadler W; Weichselbaum R; Nolen J; Kao CM; Chitneni SK; Rotsch DA; Szmulewitz RZ; Chen CT
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630292
[TBL] [Abstract] [Full Text] [Related]
14. Development of Radiopharmaceuticals for NPY Receptor-5 (Y5) Nuclear Imaging in Tumors by Synthesis of Specific Agonists and Investigation of Their Binding Mode.
Bodin S; Peuker LC; Jestin E; Alves ID; Velasco V; Ait-Arsa I; Schollhammer R; Lamare F; Vimont D; MacGrogan G; Hindié E; Beck-Sickinger AG; Morgat C
Bioconjug Chem; 2023 Nov; 34(11):2014-2021. PubMed ID: 37556437
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Stangl-Kremser J; Sun M; Ho B; Thomas J; Nauseef JT; Osborne JR; Molina A; Sternberg CN; Nanus DM; Bander NH; Tagawa S
Prostate; 2023 Oct; 83(14):1351-1357. PubMed ID: 37424145
[TBL] [Abstract] [Full Text] [Related]
16. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
[TBL] [Abstract] [Full Text] [Related]
17. Dimethylarginine Dimethylaminohydrolase - 1 expression is increased under tBHP-induced oxidative stress regulates nitric oxide production in PCa cells attenuates mitochondrial ROS-mediated apoptosis.
Asha Parveen SM; Kami Reddy KR; Ummanni R
Nitric Oxide; 2023 Sep; 138-139():70-84. PubMed ID: 37423418
[TBL] [Abstract] [Full Text] [Related]
18. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
[TBL] [Abstract] [Full Text] [Related]
19. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract] [Full Text] [Related]
20. Intercomparison of S-Factor values calculated in Zubal voxelized phantom for eleven radionuclides commonly used in targeted prostate cancer therapy.
El Bakkali J; Doudouh A; El Bardouni T; Ghalbzouri TEL; Yerrou R
Phys Eng Sci Med; 2022 Dec; 45(4):1251-1256. PubMed ID: 36315382
[TBL] [Abstract] [Full Text] [Related]
[Next]
